Anthem and Resurgens sign agreement on clinical data integration
Anthem Blue Cross and Blue Shield has entered into a multi-year provider network agreement with US-based Resurgens Orthopaedics on clinical data integration.
The agreement also includes initiatives to improve digital connectivity for minimising administrative burdens, enhancing processes, and providing patient-centred care.
Resurgens patients under Anthem health plans can benefit from improved health outcomes.
Comprising nearly 100 physicians in the Atlanta metro area, Resurgens provides patient-centred orthopaedic and spine care to the residents of Georgia and the southeastern region.
Resurgens Orthopaedics chairman Raj Bhole said: 'We are excited to continue our valued partnership with Anthem Blue Cross and Blue Shield of Georgia.
'With 25 office locations, Resurgens Orthopaedics is able to provide Anthem members convenient access to high-quality musculoskeletal care and sub-speciality trained physicians in the communities where they live and work.'
Resurgens offers specialised expertise and experience in joint replacement, sports medicine, trauma care, and orthopaedic surgery.
Anthem Blue Cross and Blue Shield president Robert Bunch said: 'Our continued partnership with Resurgens Orthopaedics reinforces our commitment to complete musculoskeletal care for our members.
'Resurgens Orthopaedics shares our dedication to whole health and serving members across their health journey as seen in their comprehensive care offerings from injury diagnosis and treatment to rehabilitation and imaging services.'
Last month, nonprofit healthcare provider Inova signed a multi-year agreement with Anthem Blue Cross and Blue Shield in Virginia to continue providing healthcare service access for plan members of Anthem.
In October the previous year, Vera Whole Health partnered with Anthem Blue Cross and Blue Shield in Connecticut to introduce an advanced primary care model in Hartford.
"Anthem and Resurgens sign agreement on clinical data integration" was originally created and published by Hospital Management, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Hospital Leaders to Speak at HFMA 2025 Conference on Successful Use of AI in Utilization Management
Experts from Stormont Vail Health will share achievements using MCG artificial intelligence to improve hospital revenue cycle DENVER, June 12, 2025 /PRNewswire/ -- MCG Health, part of the Hearst Health network and an industry leader in technology-enabled, evidence-based guidance, announces three of its hospital client partners from Topeka-based Stormont Vail Health will present at the HFMA Annual Conference happening June 22-25, 2025, in Denver, Colorado. The HFMA event is widely known for bringing together over 4,000 healthcare finance professionals to share new strategies, best practices, and valuable resources. Stormont Vail's VP Quality and Population Health, Chad Yeager, MSN, RN; Medical Director of Utilization Review and Physician Advisor, Sri Suravarapu, MD; and System Director of the Revenue Cycle, William "Bill" Lane, BS, CHFP, will present the session, "Utilizing AI and Automation to Streamline Utilization Review and Protect Hospital Revenue," on Tuesday, June 24, 2025, from 2:00 p.m. to 2:25 p.m. MDT. This presentation will cover several topics including: How MCG Indicia software (enhanced with AI capabilities) has improved medical necessity documentation and increased hospital staff efficiency The sources of EHR data that are beneficial in determining medical necessity and priority for patient admissions Opportunities to improve existing medical necessity documentation workflows within a hospital EHR platform "AI has revolutionized how we approach utilization review, enabling our teams to streamline processes and focus on high-value tasks," said Chad Yeager, MSN, RN. "At the HFMA 2025 Conference, we'll share how these innovative AI tools not only enhanced our staff's productivity but also significantly improved the quality of patient care, ensuring swift and appropriate admission decisions upfront while maximizing our hospital's operational efficiency." "By leveraging the natural language processing features of MCG Indicia Synapse, we've been able to protect our hospital's revenue cycle while simultaneously reducing administrative burdens on our staff," said Sri Suravarapu, MD. "Our presentation will showcase practical strategies and results, offering actionable insights for hospital leaders eager to optimize their workflows, drive evidence-based patient care, and stay ahead of the curve in a rapidly evolving healthcare landscape." For those interested in attending the annual HFMA Conference, registration details and additional information can be found at About Stormont Vail HealthStormont Vail Health is a nonprofit integrated health system that has served the healthcare needs of Kansas for more than 130 years. Stormont Vail has been recognized as a Magnet® organization since 2009 by the American Nurses Credentialing Center. It is composed of Stormont Vail Hospital in Topeka, a 586-bed acute care hospital, Stormont Vail Flint Hills Hospital in Junction City, a 92-bed acute care hospital, Stormont Vail Health Manhattan Campus, a primary care, specialty care, and imaging clinic, and Cotton O'Neil Clinic, a multi-specialty physician group with more than 500 providers, including more than 270 physicians. Learn more at About MCG HealthMCG, part of the Hearst Health network, provides unbiased clinical guidance that gives healthcare organizations confidence in delivering patient-centered care. MCG's artificial intelligence and technology, infused with clinical expertise, enable its clients to prioritize and simplify their work. MCG's world-class customer service ensures that clients maximize the benefits of licensing MCG solutions – demonstrating improved clinical and financial outcomes. For more information visit About Hearst HealthThe mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies — FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health — elevate care by informing and empowering participants across the health journey. To learn more, visit and follow @Hearst Health on LinkedIn. View original content to download multimedia: SOURCE MCG Health Sign in to access your portfolio
Yahoo
21 minutes ago
- Yahoo
Non-alcoholic Steatohepatitis Biomarkers Market to Hit USD 9.1 Billion by 2032
The NASH Biomarkers Market Growth is driven by AI-Based Diagnostics, Biomarker Innovations and Non-Invasive Testing Technologies. Austin, June 12, 2025 (GLOBE NEWSWIRE) -- Non-alcoholic Steatohepatitis Biomarkers Market Size & Growth Analysis: According to SNS Insider, the Non-alcoholic Steatohepatitis Biomarkers Market was valued at USD 1.14 billion in 2023 and is projected to reach USD 9.1 billion by 2032, growing at a CAGR of 25.9% during the forecast period 2024-2032. The increasing global prevalence of NASH, coupled with the rising adoption of non-invasive diagnostic tools, is significantly driving market growth. Additionally, advancements in biomarker research, propelled by AI-based diagnostic solutions and biomarker assay innovations, are fostering rapid market a Sample Report of Non-alcoholic Steatohepatitis Biomarkers Market@ Market Overview The increasing burden of NASH, a serious variant of non-alcoholic fatty liver disease (NAFLD), has propelled the need for effective diagnostic solutions. Invasive, costly, and complication-ridden traditional liver biopsies have given way to the increasing dependence on non-invasive biomarker-based diagnostic solutions. The increase in the prevalence of obesity, metabolic syndrome, and diabetes has also been a major driver in fueling the growing patient base of NASH, which has in turn led to increased biomarker demand. Industry leaders are concentrating on AI-based biomarker assays, proteomic and metabolomic innovation, and strategic partnerships to improve the detection and monitoring of NASH. Pharmaceutical organizations and CROs are leading the charge, using biomarker-driven strategies to enhance clinical trial effectiveness and streamline drug development. With regulatory approval backing innovative biomarker assays and increasing investment in biomarker studies, the market is expected to grow significantly over the forecast period. Major Players Analysis Listed in this Report are: GENFIT (NIS4™, Elafibranor) Gilead Sciences (Selonsertib, Cilofexor) AstraZeneca (Dapagliflozin, Epanova) Novartis AG (Tropifexor, LJN452) GE Healthcare (LiverMultiScan, FibroScan) Siemens Healthineers (ADVIA Centaur® CP Immunoassay System, Atellica® Solution) Bristol-Myers Squibb (Pegbelfermin, BMS-986036) Pfizer Inc. (PF-06865571, PF-05221304) Akero Therapeutics (Efruxifermin, AKR-001) 89bio (Pegozafermin, BIO89-100) Non-alcoholic Steatohepatitis Biomarkers Market Report Scope Report Attributes Details Market Size in 2023 US$ 1.14 billion Market Size by 2032 US$ 9.1 billion CAGR CAGR of 25.9% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Analysis By Type In 2023, the serum biomarkers segment led the market, accounting for 33% of total revenue. Serum biomarkers such as liver enzyme panels and inflammatory markers are much loved because of ease of usage, availability, and high precision of detection for NASH. In addition, demand for non-invasive methods for diagnosis and combination of AI-driven algorithms for detecting biomarkers is also promoting growth in this leading segment. The apoptosis biomarkers segment is expected to register the highest growth during the forecast period. Apoptosis biomarkers, including cytokeratin-18 (CK-18), are increasingly finding favor as they can offer insights into hepatocyte death and disease progression. Increased use of apoptosis biomarkers in clinical studies and their possible use in patient stratification for therapeutic interventions are some of the most important factors fueling their faster growth. By End-use The pharma and CRO industry segment held the highest market share of 39% in 2023. The segment's dominance is due to the growing dependence of pharmaceutical firms on biomarker-based approaches to drug discovery and clinical trials. NASH continues to be a prime area of interest for drug development, with several candidates in late-stage trials. CROs are instrumental in biomarker validation, expediting drug approvals, and increasing the effectiveness of clinical research, further increasing market share. The diagnostic laboratory segment is also expected to emerge as the growth leader over the next few years. Growing needs for sophisticated diagnostic solutions, and the increased choice for biomarker-based non-invasive tests, are driving growth in diagnostic laboratories focused on identifying NASH. Growing knowledge of the importance of early diagnosis by healthcare professionals and patients will propel this segment further. Non-alcoholic Steatohepatitis Biomarkers Market Segmentation By Type Serum Biomarkers Oxidative Stress Biomarkers Hepatic Fibrosis Biomarkers Apoptosis Biomarkers Others By End-use Pharma & CRO Industry Diagnostic Labs Hospitals Academic Research Institutes For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ Regional Analysis North America dominated the NASH Biomarkers Market in 2023 with 40% of overall market share. The region is influenced by a well-developed healthcare infrastructure, significant research and development expenditure, and high NASH prevalence as a result of obesity and metabolic disorders. The presence of prominent pharmaceutical and diagnostic firms also fuels market growth. The Asia Pacific region is anticipated to have the highest growth during the forecast period. The increasing NAFLD and NASH burden, rising healthcare investments, and adoption of sophisticated biomarker-based diagnostic solutions are driving regional market growth. Increasing government initiatives and regulatory backing for non-invasive diagnostics further boost the market potential in this region. Recent Developments In September 2024, Siemens Healthineers released a next-generation NASH biomarker assay integrating multiple serum-based markers via AI algorithms to enhance diagnostic accuracy. The assay received FDA clearance for clinical use. In January 2025, AstraZeneca and Novo Nordisk collaborated to develop a biomarker platform combining genomic, proteomic, and metabolomic data to advance personalized NASH treatments. Statistical Insights and Trends Reporting The global prevalence of NASH was estimated at 5% to 6% of the adult population in 2023, with North America and Europe exhibiting the highest disease burden. North America accounted for 45% of total NASH biomarker-based diagnostic tests conducted, followed by Europe at 30%, with Asia-Pacific witnessing a rapid rise in test adoption. The number of biomarker assays performed globally for NASH is projected to grow 4x between 2020 and 2032, driven by increasing non-invasive diagnostic adoption. Global research funding for NASH biomarkers exceeded USD 2.5 billion in 2023, with major contributions from biotech firms and academic institutions. Government and private healthcare expenditures on NASH diagnostics and treatment surpassed USD 8 billion, reflecting growing investments in disease management. Buy a Single-User PDF of Non-alcoholic Steatohepatitis Biomarkers Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 6. Competitive Landscape 7. Non-alcoholic Steatohepatitis Biomarkers Market by Type 8. Non-alcoholic Steatohepatitis Biomarkers Market by End Use 9. Regional Analysis 10. Company Profiles 11. Use Cases and Best Practices 12. Conclusion About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Exoskeleton Market Research and Global Forecast Report 2025-2030: Powered Exoskeletons Lead Growth with Robust Investment Activities, Industrial Adoption Amplifies Expansion
The exoskeleton market is projected to grow from USD 0.56 billion in 2025 to USD 2.03 billion by 2030, with a CAGR of 29.4%. Exoskeletons enhance mobility for those with physical impairments and reduce industrial workers' strain, boosting demand in healthcare and manufacturing. The rise in the elderly population and home rehabilitation heightens this need. Technological advancements, including AI and improved materials, are enhancing exoskeleton functionality and availability. Significant investments, such as those in German Bionic and Verve Motion, highlight the industry's growth potential. Key players include Ekso Bionics, Ottobock, and CYBERDYNE Inc. Exoskeleton Market Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Exoskeleton Market by Component (Sensors, Actuators, Power Systems, Controllers, Software), Functionality (Assistive, Rehabilitative, Augmentative, Preventive), Type (Powered, Passive, Hybrid), Body Part (Lower, Upper, Full Body) - Global Forecast to 2030" has been added to offering. The exoskeleton market is anticipated to grow significantly, from USD 0.56 billion in 2025 to USD 2.03 billion by 2030, with a robust CAGR of 29.4% This surge is driven by its expanding integration into healthcare and manufacturing sectors, aiding mobility for physically impaired individuals while reducing industrial workers' physical strain. An aging population and increased home care rehabilitation further propel the demand. The evolution of technology, including AI, sensors, and lightweight materials, enhances the affordability, accessibility, and performance of exoskeletons. Investment from both public and private sectors will continue to bolster product innovation and market growth. Key players in the market include Ekso Bionics (US), Ottobock (Germany), DIH Medical (Switzerland), Comau (Italy), Myomo Inc. (US), CYBERDYNE Inc. (Japan), Lifeward Ltd. (Israel), Hyundai Motor Group Robotics LAB. (South Korea), B-Temia (Canada), Rex Bionics Ltd. (New Zealand), among Exoskeletons Gaining Momentum The powered exoskeleton sector is witnessing robust growth, exemplified by the strategic investments and increased investor confidence in its commercial viability. German Bionic, an innovator in electrically powered exoskeletons, secured over USD 16.3 million in an extended Series A funding round in December 2023. This investment aims to enhance collaboration with Mubea and scale production for better market deployment. Additionally, Verve Motion, a Cambridge-based startup specializing in robotic exosuits, raised USD 20 million in a Series B funding round to further its market reach. These developments highlight the strategic investment in powered exoskeleton technology, poised to revolutionize industrial automation, injury prevention, and workforce Sector's Rapid Adoption The industrial sector is increasingly adopting exoskeletons to boost worker safety, mitigate fatigue, and enhance productivity. They are essential in industries such as manufacturing, logistics, and assembly lines, where repetitive tasks are prevalent. Exoskeletons help mitigate musculoskeletal injuries by supporting the lower back, shoulders, and legs, thereby reducing the occupational health costs and improving Leading Europe Germany leads the European exoskeleton market with strong industrial demand and innovation in healthcare, supported by significant private investments. Its robust manufacturing and logistics sectors actively integrate exoskeletons to enhance workforce efficiency and reduce musculoskeletal injuries. Companies like German Bionic are at the forefront, raising over USD 16.3 million to advance their product offerings, with models like Apogee and Apogee+ significantly impacting logistics, retail, and healthcare sectors with their ergonomic Insights Include: Analysis of market drivers, restraints, opportunities, and challenges. Insights into upcoming technologies, R&D activities, and product launches. Comprehensive information on lucrative markets. In-depth competitive assessments and strategic analysis of leading players. Key Attributes: Report Attribute Details No. of Pages 255 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $0.56 Billion Forecasted Market Value (USD) by 2030 $2.03 Billion Compound Annual Growth Rate 29.4% Regions Covered Global Market Dynamics Drivers Rising Demand for Robotic Rehabilitation Solutions From Healthcare Sector Increased Adoption in Industrial and Manufacturing Sectors Increased FDA Approvals for Medical Exoskeletons Challenges High Cost of Ownership Comfort and Movement Interference for Workers Power Supply Limitations and Operational Downtime Opportunities Integration of Exoskeletons With AI and IoT Technologies Increasing Adoption of Exoskeletons in Military and Defense Sectors Case Studies Enhancing Worker Ergonomics and Productivity At John Deere With Comau's Mate-Xt Wearable Exoskeleton Enhancing Logistics Operations and Worker Well-Being At Fiege Group With German Bionic AI-Powered Exoskeleton Technology Enhancing Worker Safety and Productivity in Tunnel Construction At Granite Construction With Levitate Technologies Exoskeletons Reducing Physical Strain in Truck Maintenance At Man Truck & Bus With Help of Suitx Technology by Ottobock Ford Motor Company Enhances Worker Safety and Reduces Injuries With Ekso Bionics Eksovest Company Profiles Ekso Bionics Ottobock DIH Medical Comau Myomo Inc. Cyberdyne Inc. Lifeward Ltd. Hyundai Motor Group Robotics Lab. B-Temia Rex Bionics Ltd. Able Human Motion Laevo Exoskeletons German Bionic Systems GmbH Levitate Technologies, Inc. Fourier Trexo Robotics Wandercraft Agade Europe Technologies Archelis Inc. P&S Mechanics Co., Ltd. Rb3D Japet Medical Devices Proteso S.R.L. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Exoskeleton Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
